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Abstract
Cytokines can be functionally active across species barriers. Bovine IL-10 has an amino acid sequence identity with human
IL-10 of 76.8%. Therefore, the aim of this study was to evaluate whether bovine IL-10 has immunomodulatory activities on
human monocytes and dendritic cells. Peripheral blood monocytes were isolated from healthy donors, and used directly or
allowed to differentiate to dendritic cells under the influence of IL-4 and GM-CSF. Recombinant bovine IL-10 inhibited TLR
induced activation of monocytes, and dose-dependently inhibited LPS-induced activation of monocyte-derived DCs
comparable to human IL-10. By using blocking antibodies to either bovine IL-10 or the human IL-10 receptor it was
demonstrated that inhibition of monocyte activation by bovine IL-10 was dependent on binding of bovine IL-10 to the
human IL-10R. These data demonstrate that bovine IL-10 potently inhibits the activation of human myeloid cells in response
to TLR activation. Bovine IL-10 present in dairy products may thus potentially contribute to the prevention of necrotizing
enterocolitis and allergy, enhance mucosal tolerance induction and decrease intestinal inflammation and may therefore be
applicable in infant foods and in immunomodulatory diets.
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Introduction
Dietary components are capable of modulating intestinal
immune responses [1,2]. Dairy products, including cow’s milk,
are widely consumed in Western societies and contain a wide range
of immunoprotective factors such as immunoglobulins, lactoferrin,
anti-microbial enzymes and cytokines. Bovine IL-10 was found to
have an amino acid sequence identity of 76.8% with human IL-10,
indicating that bovine IL-10 may exert functional effects on human
immune cells [3,4,5,6]. Therefore, bovine IL-10 present in dairy
and dairy related products could potentially have immunomodu-
latory activity in the human consumer. Functional cross species
activity of cytokines has been reported for chicken IFN-c and turkey
IL-2 [5,6], and both porcine IL-2 and human IL-2 were reported to
enhance proliferation of human, bovine, porcine and murine cells in
vitro [3]. Also, human IL-10 is functionally active on a mouse mast
cell line, but mouse IL-10 was not functionally active on a human B
cell line [7]. Together these findings indicate that cytokines can be
functionally active across species. The potential cross-species
bioactivity of IL-10 depends mostly on the sequence identity of
the IL-10 receptor (IL-10R) binding sites [4] and three dimensional
structure of the proteins involved.
Biologically active IL-10 binds to the IL-10R, which is
expressed on monocytes, macrophages, dendritic cells (DCs),
NK cells, T cells and B cells. IL-10 is bound as a homodimer at
two sites by both the IL-10R1 dimer and the IL-10R2 dimer,
resulting in four IL-10/IL-10R interaction sites [8,9,10]. The IL-
10R1 dimer binds the IL-10 molecule with high affinity;
subsequently, this complex is recognized by the low affinity IL-
10R2 dimer. IL-10 bound to IL-10R1 activates phosphorylation of
Jak1 and Tyk2, which leads to Signal Transducer and Activator of
Transcription 3 activation [11]. Signal Transducer and Activator
of Transcription 3 translocates to the nucleus and activates
Suppressor of Cytokine Signalling-3 [11,12], resulting in suppres-
sion of MyD88 - NFkB activated TLR-inducible cytokines like IL-
1b, IL-6 and TNF-a [13,14,15,16,17]. These cytokines are
selectively inhibited by IL-10 in a dose-dependent manner [18,19].
IL-10 is a potent cytokine and essential in controlling excessive
immune responses to infections, thereby reducing immunopathol-
ogy [20]. T cell dependent and T cell independent IgA class
switching and production can be initiated by IL-10 in secondary
immune organs and in the lamina propria [21,22,23]. IL-10 is
involved in tolerance induction and immune regulation in both the
innate and adaptive immune system. IL-10 can also inhibit
homing of DC’s to the draining lymph node [24], and IL-10
treated DCs can induce tolerance [25]. The maturation and
activation induced expression of CD40, CD80 and CD86 by
macrophages and DCs can be inhibited by IL-10 [26,27], affecting
the ability to stimulate T cells. Indeed, IL-10-exposed APCs fail to
induce IFN-c production by Th1 cells [28,29].
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IL-10 can directly regulate T cell responses and has been shown
to be related to successful allergen immunotherapy [30,31,32]. IL-
10 excreted by transfected Lactococcus lactis in the lumen of the
intestine of mice can induce IL-10 production by cells of the
Peyers patch and prevent allergic sensitization to food [33]. Next
to this, in a neonatal rat model, decreased necrotising enterocolitis
(NEC) correlated with increased in situ IL-10 production [34].
These findings show the potential significance of the presence of
IL-10 in the intestine.
In this report, we investigated whether bovine IL-10 could exert
functional activity on human monocytes and dendritic cells.
Bioactive bovine IL-10 could potentially be used for the
prevention of inflammatory diseases as NEC and allergy in infant
nutrion, or in immunomodulating diets for patients suffering from
intestinal inflammatory disorders. We show that bovine IL-10 is
recognized by the human IL-10 receptor and dose-dependently
inhibits cytokine production and surface marker expression during
LPS induced DC maturation.
Materials and Methods
IL-10 sequence analysis
IL-10 sequences were obtained from the online databases of
NCBI (http://www.ncbi.nlm.nih.gov/) and UniProt (http://www.
uniprot.org/). Existing signal peptide data or signalP 3.0 (http://
www.cbs.dtu.dk/services/SignalP/) were used to identify IL-10
signal peptides, which were removed before performing the
sequence alignment. Sequence alignment was done in BioEdit
(version 7.0.9.0) using ClustalW Multiple Alignment with default
settings. Subsequently, the amino acid sequence identity was
calculated using the sequence identity option in BioEdit. Accession
numbers of the IL-10 sequences are: Human, UniProt, P22301;
Bovine, UniProt, P43480, Epstein-Barr virus (EBV), UniProt,
P03180; Rat, NCBI, EDM09836; Sheep, NCBI, CAA82546;
Mouse, NCBI, AAI37845; Pig, NCBI, CAL29498 and Papiine
herpesvirus 1 (PapHerp), NCBI, AAF23949.
Three-dimensional modeling of bovine IL-10
The dimeric structure of human IL-10 (PDB entry: 1j7v,
resolution 2.9 A˚) was used as a template to model the dimeric
bovine IL-10 protein using the program MODELLER (version
9v8 [35,36]), which incorporates the CVFF force field [37].
Stereochemical quality of the homology models was assessed using
the program PROCHECK [38]. Protein folding quality was
verified using the program PROSAII [39], which independently
evaluates the compatibility of each residue to its environment.
PBMC isolation
Peripheral blood mononuclear cells (PBMCs) were diluted 1:1
in IMDM (Gibco-BRL, Paisley, Scotland) and isolated by gradient
centrifugation on Ficoll-Plaque PLUS (Amersham Biosciences,
Uppsala, Sweden) for 5 minutes at 200 g and subsequently for
15 min. at 500 g (without brake at 20 uC). The PBMCs were
harvested from the Ficoll layer, gently resuspended in IMDM and
washed two or three times in IMDM.
Monocyte isolation and stimulation
Monocytes from freshly isolated PBMCs were labeled with
MicroBeads conjugated to mouse IgG2a monoclonal anti human
CD14 antibodies (130-050-201, Myltenyi Biotec, Germany), and
isolated using the quadroMACS (Myltenyi Biotec) according to the
manufacturers descriptions. Briefly, cells were incubated with
MicroBeads for 15 minutes at 4uC, washed with MACS buffer,
centrifuged and resuspended in MACS buffer. The MACS
columns were placed in the quadroMACS and rinsed. Subse-
quently, the cell suspension was added, rinsed and the columns
removed from the quadroMACS; labeled cells were collected in a
new tube by rinsing with MACS buffer and the supplied plunger.
Purity of the CD14+ cell population was between 90 and 95%, as
determined by flow cytometric analysis (FACS Canto II BD
Biosciences, San Jose, CA, USA) by labeling the cells with mouse
IgG2a anti human CD14 APC or an isotype control (clone M5E2,
555399 or 555576, BD Biosciences). Myltenyi Biotec indicated
that clone M5E2 was not used on the microbeads used for
isolation of the cells. After MACS sorting monocytes were
resuspended in IMDM +1% Yssels medium [40] +1% penicillin
and streptomycin (Gibco).
Recombinant bovine IL-10
The recombinant bovine IL-10 was produced in house.
Therefore the bovine IL-10 cDNA sequence encoding the mature
part of the protein was cloned in pET15bGW essentially as
described previously for rhinoceros IFN-c [41]. Vector
pET15bGW encodes for an N-terminal tag containing 6 histidine
residues (his6-tag) under control of a T7 promoter. This tag
enables purification of recombinant protein by immobilized metal
affinity chromatography (IMAC). Protein production, purification
by IMAC endotoxin removal and refolding was essentially
performed as described previously for carp CXCL8 chemokines
[42]. The sequence of recombinant bovine IL-10 used in the cell
culture experiments is identical to the bovine IL-10 sequence
showed in Figure 1 (NCBI database), as was confirmed by
sequencing the IL-10 coding insert of the vector (Baseclear,
Leiden, The Netherlands).
IL-10R inhibition
Monocytes were stimulated with 1 mg/ml LPS (S. enterica, Sigma
Aldrich, St Louis, USA), 2 mg/ml peptidoglycan (S. aureus, Fluka,
Buchs Switzerland) and 2 mg/ml flagellin (S. typhimurium, Invivo-
Gen, Toulouse, France). Human (200-10, Peprotech, London) or
bovine IL-10 was used at a concentration of 10 ng/ml. To block
the biological activity of recombinant bovine IL-10, 50 mg/ml
total chicken IgY isolated from egg yolks of chicken immunized
with recombinant bovine IL-10 was used. Antibodies isolated from
egg yolks of non-immunized chicken (50 mg/ml) were used as a
negative control. To block the human IL-10R, 5 mg/ml rat IgG2a
anti human IL-10R (CDw210) (Clone 3F9, 556011, BD
Biosciences) and an isotype control (554687, BD Biosciences)
were used. Antibodies were added to the cells and incubated at
37uC and 5% CO2 for 30 minutes prior to addition of other
stimuli. Monocytes were stimulated with different TLR ligands
with or without bovine IL-10 for 24 hours at 37uC and 5% CO2.
LPS and a widely used dose [12,19] of 10 ng/ml human or bovine
IL-10 were added and incubated for 24 hours at 37uC and 5%
CO2. Cell culture supernatants were collected and stored at
280uC for later cytokine analyses.
DC generation and stimulation
Monocytes for DC generation were purified from freshly
isolated PBMCs by density centrifugation using Percoll (GE
Healthcarespec. grav. 1.13060.005 g/ml, ,25 mOsm/kg H20).
Standard isotone Percoll was prepared by adding 1 part PBS to 9
parts Percoll and used to make three layers of different densities of
Percoll (2.5 ml 60%, 5.0 ml 45% and 2.5 ml 34.2% in HBSS in a
15 ml tube). Cells (in HBSS +10% FBS) were gently added on top
of the Percoll layers (max 40*106 cells) and centrifuged at 18–22uC
for 45 minutes at 1750 g without brake. Monocytes were collected
and transferred to a new tube, centrifuged again (20 minutes at
Immunomodulation in Humans by Bovine IL-10
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Figure 1. Comparison of human and bovine IL-10 in the human IL-10R. A: ClustalW sequence alignment of IL-10 from different species. IL-10
sequences were retrieved from the NCBI and Uniprot databases and analyzed for signal peptides (SignalP 3.0) which were removed from the
sequences before performing the alignment (18 amino acids for human and bovine IL-10). At the top left the overall sequence identity is shown. In
grey (Ib) and black (Ia) background shading the IL-10 receptor 1 binding sites are indicated as published by Josephson [8]. The underlined residues
indicate.5 A˚2 surface area in IL-10RA site I. At the bottom of each row the consensus (*) sequence is shown; ‘‘.’’ and ‘‘:’’ indicated homologous amino
acids. B: Bovine IL-10 was modeled using human IL-10 in the human IL-10/IL-10R complex as template. The human IL-10R is shown in green and
amino acid substitution between human and bovine IL-10 are depicted in cyan. Cysteine residues are colored yellow, the amino acid colored red
(indicated with an arrow for one of the two IL-10 chains) is His 44, which is and amino acid substitution in close contact with the human Il-10R. C: The
same model as in B, but displayed using spheres.
doi:10.1371/journal.pone.0018188.g001
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1000 g) and washed two times with 1% FBS in PBS (Gibco,
16000-044). Isolated monocytes were cultured in FBS free
CellGroD medium (CellGenix, 2005) with pen/strep (Gibco,
15140) at a concentration of 1*106 cells/ml. 40 ng/ml recombi-
nant human GM-CSF (Peprotech, 300-03) and 20 ng/ml
recombinant human IL-4 (Peprotech, 200-04) were added and
refreshed every second day. On day 6, expression of surface
markers was analyzed using flow cytometry (FACS Calibur, BD
Biosciences).
On day 6, DCs were stimulated with 50 ng/ml (or 1000 ng/ml,
data not shown) LPS (S. enterica, Sigma Aldrich, St Louis, USA) for
48 hours in the absence or presence of IL-10. Cell free supernatants
were collected and stored at 280uC until analysis. DCs were
collected and cell surface marker expression was analyzed.
Cell Surface marker analysis
DCs were stained with FITC or PE labeled mouse IgG1
antibodies anti human CD40 (FITC), CD80 (PE), CD83 (FITC),
CD86 (FITC), CD1a (PE), MR (CD206, PE) or HLA-DR (PE)
(555588, 557117, 556910, 555657, 555807, 555954, 555812, BD
Biosciences) or isotype controls (PE 555749, FITC 555748, BD
Biosciences), according to the manufacturers descriptions. Cells
were incubated at room temperature for 30 minutes in the dark.
Subsequently, cells were centrifuged, supernatant discarded,
200 ml FACS Buffer (BD Biosciences) added, and analyzed for
surface marker expression by flow cytometric analysis.
Human cytokine measurements
Human cytokine concentrations in cell culture supernatants
were determined using the cytometric bead array flex sets (BD
Biosciences) and incubations were performed in the recommended
Protein Master Buffer Kit (BD Biosciences). Briefly, 50 ml
supernatant was incubated with capture beads in 50 ml Capture
Bead Diluent for one hour at room temperature. Next, PE
Detection Reagent in 50 ml Detection Reagent Diluent was added
and incubated for two hours at room temperature in the dark. For
the standard curve, the provided lyophilized recombinant
cytokines were used and assayed together with the samples. After
incubation the samples were centrifuged, supernatant discarded
and 200 ml Wash Buffer was added. The samples were analyzed by
flow cytometric analysis (FACS Canto II, BD Biosciences).
Bovine IL-10 ELISA
A bovine IL-10 specific capture ELISA was developed in house
using an anti-bovine IL-10 specific monoclonal (MCA2110, AbD
Serotec, Oxford, UK) as a capture antibody and biotinylated anti-
bovine IL-10 IgY as a detecting antibody. The anti-IL-10 IgY had
been affinity purified against in house produced recombinant
bovine IL-10 coupled to CNBr-activated Sepharose 4B from eggs
of chickens that had been immunized repeatedly with recombinant
bovine IL-10.
Statistical analysis
Statistical analysis was performed with PASW Statistics SPSS
version 17.0.3. Cytokine production levels upon stimulation with
bacterial ligands vary greatly between donors. Therefore we tested
the inhibitory capacity within the donor. We performed a
generalized linear model after logarithmic transformation of the
cytokine data: cytokine production level = donor (stimulus *
inhibitor). Stimulus (LPS, PGN or Flagellin) and inhibitor
(whether IL-10 was added or not) were included as fixed factors
(this will compare groups) and the interaction term (*) tests the
effect of the inhibitor in relation to the stimulus used.
Statistical analysis of the dose-dependent modulation of DC
surface marker expression levels by bovine IL-10 was performed
using a one by one correlation model: surface marker expression
level or cytokine concentration = bovine IL-10 concentration.
The bioactivity between bovine and human IL-10 was
compared using a univariate general linear model: cytokine
production = IL-10 source (bovine or human) * IL-10
concentration. Low p-values would indicate a difference between
human and bovine IL-10.
Results
Identification of human IL-10R binding sites in bovine IL-
10
In order to make a more detailed comparison possible of
potential interactions between bovine IL-10 and human IL-10R,
IL-10 sequences of different species were aligned and the IL-10R
binding sites indicated (Figure 1). IL-10 sequences were obtained
from the NCBI and Uniprot online databases, and SignalP 3.0 was
used to identify signal peptides. Next, signal peptides were
removed from the sequences before performing the ClustalW
Multiple Alignment. Data on the IL-10R binding sites (obtained
from Josephson [8]), were in line with the receptor binding sites
reported by Reineke [9]. The IL-10R binding sites in IL-10, as
published by Josephson, are indicated in Figure 1A, with black (Ia)
and grey (Ib) background colors. The interactions between IL-10
and the IL-10R are largely determined by residues of IL-10 in
close contact with the receptor. Therefore, residues burying a
surface area of more than 5 A˚2 into human IL-10R1 [8] are
underlined in Figure 1A, allowing evaluation of potential
consequences of sequence differences between human and bovine
IL-10 in the human IL-10R binding sites.
Human and bovine IL-10 were found to have an amino acid
sequence identity of 76.8% (Figure 1A). Twenty-nine percent (11
out of 38) of the amino acid substitutions are present in the first 20
amino acids of the IL-10 sequence. The IL-10R binding site Ia
(amino acid residues 138–149) is identical for human and bovine
IL-10. Divided over the three other IL-10R binding sites, bovine
IL-10 contained nine amino acid substitutions compared to
human IL-10 (summarized in Table 1). Seven of the nine different
residues bury more than 5 A˚2 in the IL-10R binding site and
therefore are expected to contribute to the binding of IL-10 to the
IL-10R. Three amino acid substitutions had a different polarity,
and different hydrophobicity indexes. These three non-homolo-
gous substitutions occurred in the Ib IL-10R binding sites and two
of them buried more than 5 A˚2 in the IL-10R binding site. Six of
Table 1. Summary of bovine IL-10 amino acid substitutions in
human IL-10R binding sites.
Binding site
(residues)
Ib
(20–28)
Ia
(34–46)
Ia
(138–149)
Ib
(151–159) Total
No. residues 9 13 12 9 43
Substitutions 3 2 0 4 9 (21%)
- Homologous 2 2 - 3 7 (78%)
Substitutions .5 A˚2 2 2 - 3 7
- Homologous 1 2 - 2 5 (71%)
Data are obtained from a ClustalW Multiple alignment as shown in Figure 1A. Of
the amino acid substitutions and the substitution burying .5 A˚2 in the human
IL-10R [9] the number of homologous amino acid substitutions is indicated.
doi:10.1371/journal.pone.0018188.t001
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the nine amino acid substitutions had similar polarity and none
had opposite (positive versus negative) polarity.
To support the linear peptide analysis, a 3D model of bovine
IL-10 bound to the human IL-10R was built, based on the
available crystal structure of the human IL-10/IL-10R complex
(Figure 1B). No structural differences apart from some side chain
orientations are observed between the model of bovine IL-10
and the crystal structure of human IL-10. The majority of
amino acid substitutions between human and bovine IL-10 are
located at the surface of the IL-10 molecule. The IL-10R
binding site of IL-10 does not contain any amino acid
substitutions, except for one histidine residue (His 44) substitu-
tion. Analysis of the 3D model showed that this histidine is
located in a pocket of the receptor (Figure 1C) and is not likely
to impair IL-10R binding.
Bovine IL-10 exerts functional effects on human
monocytes through binding to the IL-10R
In order to investigate the bioactivity of bovine IL-10 on the
human immune system, we tested the effect of bovine IL-10 on
freshly isolated monocytes from three healthy donors. These
freshly isolated monocytes were stimulated with different bacterial
ligands: peptidoglycan (PGN), flagellin and lipopolysaccharide
(LPS) in the presence or absence of bovine IL-10.
Monocyte cell cultures were 90–95% pure, as determined by
flow cytometry for CD14 (data not shown). Addition of
recombinant bovine IL-10 significantly inhibited PGN, flagellin
and LPS induced IL-1b (p,0.001) and TNF-a (p,0.001)
production by monocytes as tested on three different donors
(Figure 2A). We suggest that bovine IL-10 potently inhibits TLR
induced activation. The 5-fold inhibition of TNF-a and IL-1b
production by monocytes was comparable between bovine and
human IL-10 (Figure 2B and Table 2).
Additional experiments were performed to confirm that
inhibition of TLR-induced cytokine production by monocytes
was specifically caused by bovine IL-10. Therefore, IL-10 blocking
antibodies or isotype control antibodies were pre-incubated with
bovine IL-10 and LPS, and subsequently added to the monocytes.
Addition of IL-10 blocking antibodies in combination with bovine
IL-10 completely restored the IL-1b and TNF-a production by
LPS stimulated monocytes; which was not observed when the
isotype control was used (Figure 2C).
The comparison of the sequence of bovine IL-10 with the IL-
10R binding sites on the sequence of human IL-10 (Figure 1),
confirmed that bovine IL-10 could potentially bind to the
human IL-10R. To investigate whether the functional effect of
bovine IL-10 is indeed through the binding of bovine IL-10 to
Figure 2. Bovine IL-10 can regulate TLR ligand induced
cytokine production by monocytes by binding the IL-10R.
Figures 2B-2D are box plots, showing the median (black horizontal bar),
50% data range (box) and 99% data range (error bars). On the x-axes is
the addition indicated (+) of TLR stimuli (panel A), or 10 ng/ml LPS (B–
D), 10 ng/ml IL-10 (A-D), bovine IL-10 or human IL-10R blocking
antibodies (anti bIL-10 or IL-10R) or isotype control (C–D). A: Freshly
isolated monocytes were stimulated for 24 hours with different ligands
(lipopolysaccharide (LPS); Flagellin (Flag); peptidoglycan (PGN)) with or
without recombinant bovine IL-10. IL-1b (p,0.001) and TNF-a
(p,0.001) were significantly inhibited by the three bacterial ligands
tested. Data (pg/ml) is shown for three different donors. B: Human
monocytes were stimulated with LPS and either human (white box) or
bovine (hatched box) IL-10 was added to compare the inhibitory
capacity of bovine IL-10 with human IL-10. C: To confirm that the
response is specifically inhibited by bovine IL-10 a blocking antibody
and an isotope control were pre-incubated with bovine IL-10 and LPS
and subsequently added to the monocytes. IL-1b and TNF-a production
(pg/ml) is shown of three different donors. D: In order to proof that the
bioactivity of bovine IL-10 is mediated through the IL-10R, monocytes
were pre-incubated with IL-10R blocking antibodies and subsequently
stimulated with LPS and bovine or human IL-10. Data is shown of 3
different donors.
doi:10.1371/journal.pone.0018188.g002
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the human IL-10R, additional experiments were performed with
an human IL-10R blocking antibody (anti human CDw210).
PBMC derived monocytes from three different donors were
isolated and pre-incubated with the IL-10R blocking antibody or
isotype control. Following this incubation, LPS and bovine IL-
10 were added. Blocking the IL-10R completely restored the IL-
1b and TNF-a production of LPS stimulated monocytes,
proving that bovine IL-10 binds to the human IL-10R
(Figure 2D). Addition of the isotype control resulted in TNF-a
and IL-1b production levels similar to IL-10 inhibited
monocytes. The results obtained with the IL-10R blocking
antibody showed a similar inhibition as the results from the
bovine IL-10 blocking antibody.
These results clearly demonstrate that bovine IL-10 inhibits
TLR induced cytokine production by human monocytes, through
binding to the human IL-10R.
Bovine IL-10 inhibits LPS-induced DC activation
After testing the bioactivity of bovine IL-10 on human
monocytes, experiments with DCs were performed to test if
bovine IL-10 is bioactive on other antigen presenting myeloid cells
that are potent T helper cell inducers. Freshly isolated monocytes
were differentiated into immature DCs under the influence of
human IL-4 and GM-CSF. These immature DCs from three
different donors were maturated with 50 ng/ml LPS in the
presence of several concentrations of bovine IL-10. The LPS-
induced cytokine production and cell surface marker expression
were characterized by flow cytometric analysis.
A typical example of raw flow cytometry data is shown in
Figure 3A (CD80). Maturation marker CD83 and activation
markers CD40, CD80 and CD86 were up-regulated after
stimulation with LPS. Expression of CD83 (p = 0.006), CD40
(p = 0.030), CD80 (p = 0.018) and CD86 (p = 0.012) were dose-
dependently down-regulated by bovine IL-10 (Figure 3B). Expres-
sion of mannose receptor (MR) (p = 0.002) was up-regulated with
increasing doses of bovine IL-10. The expression of HLA-DR was
not influenced by bovine IL-10 or LPS. The expression of CD1a
was inhibited after stimulation with LPS, and not affected by
bovine IL-10 (data not shown). Addition of bovine IL-10 alone did
not affect any of the analyzed surface marker expression levels
(data not shown).
Cell culture supernatant of LPS (50 ng/ml) stimulated DCs
were analyzed for IL-12p70, TNF-a, IL-1b and IL-10 levels.
Bovine IL-10 dose-dependently down-regulated the production of
IL-12p70 (p,0.001), TNF-a (p,0.001), IL-1b (p,0.001) and IL-
10 (p = 0.001) as shown in Figure 3C. Similar results were
obtained for DC’s stimulated with 1000 ng/ml LPS (data not
shown). On both, DCs and monocytes, 10 ng/ml bovine IL-10
could almost completely inhibit TLR dependent activation.
These data clearly show that bovine IL-10 dose-dependently
inhibits LPS induced surface marker expression and cytokine
production by DCs.
Bovine and human IL-10 are equally effective in
inhibiting LPS-induced DC activation
As bovine IL-10 is able to dose-dependently modulate DC
responses, a comparison of the bioactivity of bovine IL-10 and
human IL-10 was made, to verify if bovine IL-10 is equally potent
as human IL-10 on human dendritic cells. Compared to the
previous experiment, a wider range of IL-10 concentrations was
used in combination with 10 ng/ml LPS. Expression of CD40,
CD80, CD83, CD86, HLA-DR, CD1a, MR and TNF-a and IL-
12p70 production was determined for three different donors.
Human and bovine IL-10 were both equally potent in inhibiting
LPS induced CD83 (linear regression of the difference between
human and bovine IL-10: p = 0.753 and CD86: p = 0.936)
expression by LPS stimulated DCs (Figure 4A and Table 2). Also
expression of CD40 (p = 0.995), CD80 (p = 0.971), HLA-DR
(p = 0.841), CD1a (p = 0.873) and MR (p = 0.881) was not
differentially modulated between human and bovine IL-10 (data
not shown). Likewise, the TNF-a (p = 0.916) and IL-12p70
(p = 0.962) production was equally modulated by human and
bovine IL-10 (Figure 4B). From Table 2 it appears that bovine and
human IL-10 show similar inhibitory capacity for all parameters
tested.
Based on these data, we conclude that bovine and human IL-10
are equally potent in inhibiting LPS induced DC activation.
Bioavailability of bovine IL-10
As applications of bovine IL-10 in humans would depend on the
bioavailability we analyzed milk and colostrum samples for IL-10
levels by ELISA and performed an in vitro assay to assess the
survival of IL-10 in the upper digestive tract.
In colostrum samples, a range of 150–3000 pg/ml of IL-10 was
detected in 56 samples from 10 different cows, but in commercially
Table 2. Percentage inhibition of DC and monocyte activation of human and bovine IL-10.
DC monocytes
IL-12 Tnf-a CD83 CD86 IL-1b TNF-a
bo hu bo hu bo hu bo hu bo hu bo Hu
IL-10 (ng/ml) 0 100 100 100 100 100 100 100 100 100 100 100 100
0.25 102.9 52.5 143.9 92.1 130.5 128.7 106.3 105.6
0.75 30.8 49.0 88.0 74.7 125.5 114.4 83.4 99.2
2.2 28.0 16.3 55.2 25.1 125.2 60.6 99.3 83.7
6.7 8.9 6.4 13.1 4.6 90.9 72.0 67.9 62.2
20 1.5 2.1 0.9 1.3 38.2 26.2 51.0 47.3
10 30.3 23.0 14.2 6.1
Average percentage (3 donors, Figure 4) of IL-12 and TNF-a production and CD83 and CD86 expression by DCs and IL-1b and TNF-a production by monocytes (4
donors, Figure 2B) is shown compared to cells only stimulated with LPS (DC’s 10 ng/ml, monocytes 1 mg/ml). Similar findings showing the similarity in inhibitory
capacity of bovine and human IL-10 were obtained for expression of CD40, CD80, CD1a, MR and HLA-DR.
doi:10.1371/journal.pone.0018188.t002
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available milk no significant IL-10 levels were detectable (data not
shown).
To evaluate the survival of bovine IL-10 in the human upper
digestive tract, IL-10 was incubated in an electrolyte solution
containing pepsin. IL-10 was dissolved in a protein matrix and
incubated for 1 (adults) or 2 (infants) hours at different pH (pH 3
for adults, pH 4 for infants) to resemble respectively the infants
and adult stomach. After this incubation 50–60 percent of the IL-
10 was still detectable under the conditions of an infant’s stomach
and 20% for adults (data not shown).
Discussion
Dairy products form an important part of the Western diet, and
are a potential source of immunomodulatory ingredients. Bovine
milk contains cytokines like IL-10 that can have functional effects
on immunological structures in the gut mucosa. IL-10 can exert
bioactivity when present in the lumen of the gut [33] and
therefore, consumption of IL-10 may potentially modulate innate
immune responses in the intestine. The data presented here
demonstrate that bovine IL-10 is able to modulate TLR induced
cytokine production by human monocytes. Bovine IL-10 binds to
the human IL-10R and is able to dose-dependently modulate LPS-
induced DC activation, similar to human IL-10. This is in line
with the results of a detailed analysis of the cytokine receptor
binding sites, and with 3D modeling of the human IL-10R/bovine
IL-10 complex.
The recombinant bovine IL-10 used here exerted similar
inhibitory capacity and dose-dependency on dendritic cells as
human IL-10. The effects noted with human IL-10 are in line with
IL-10 studies published before [13,15]. These results demonstrate
that the amino acid substitutions between human and bovine IL-
10 do not affect the interaction between bovine IL-10 and the
human IL-10R.
Other amino acid substitutions in IL-10 may however decrease
IL-10 functionality. An extensive genomic analysis of the IL-10
gene and flanking regions of 94 Ulcerative colitis and 94 Crohn
disease patients revealed polymorphisms in the IL-10 coding gene,
of which one (R159) was in the receptor binding site, as reported
by Josephson [8,43]. However, it has not been studied in detail if
this polymorphism indeed affects IL-10 – IL-10R interactions in
colitis patients.
As far as we know, the IL-10R expression and signal transduction
is similar for monocytes and DCs with regard to TLR-dependent
activation and cytokine production [11,12,44]. Indeed, our results
show that cytokine production by monocytes and DCs could be
equally well modulated by bovine IL-10. Involvement of the human
IL-10R in the bioactivity of bovine IL-10 implies that all cell types
like T cells, B cells and NK cells expressing the IL-10R are probably
also modulated by bovine IL-10.
Figure 3. Bovine IL-10 dose-dependently inhibits DC surface marker expression and cytokine production. A: Typical example of raw
data of flow cytometric analysis. Data shown is CD80 expression during LPS induced DC maturation of one donor. The solid line indicates CD80
staining and the dashed line the isotype control. On top of the graphs is indicated whether medium, LPS or LPS plus different doses of IL-10 (ng/ml)
were used. B: Bovine IL-10 dose-dependently modulates DC surface marker expression (CD83, p = 0.002; CD40, p = 0.030; CD80, p = 0.018) during LPS
induced maturation. Relative values are shown from three different donors. Mean fluorescent intensities were divided by the isotype control and
expressed relative to the positive control (LPS, without IL-10), which was set at 100%. C: Recombinant bovine IL-10 dose dependently modulates the
production of cytokines by human DC’s during LPS induced maturation (IL-12, p =,0.001; TNF-a, p,0.001; IL-1b, p,0.001, IL-10, p,0.001). Raw data
is shown from three different donors tested. For each cytokine, a negative control (no LPS, no IL-10) is shown at the left. Data is shown in panels B
and C are from three different donors, error bars indicate standard error. On the x-axes the addition of LPS and bovine IL-10 (ng/ml) is indicated.
doi:10.1371/journal.pone.0018188.g003
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Monocytes and DCs are antigen presenting cells (APC) that are
involved in downstream activation of T cells. The modulation by
bovine IL-10 of TLR-induced cytokine responses and surface
marker expression on DCs will in turn affect their ability to
activate CD4+ T helper cells. T helper cells need co-stimulation of
CD28 by CD80 (B7-1) or CD86 (B7-2). Bovine IL-10 reduced the
upregulation of CD80 and CD86 by human DC’s and therefore is
likely to reduce T helper cell activation [45]. In addition, bovine
IL-10 also modulated IL-12 production, which affects Th1 versus
Th2 skewing. As shown in figure 3C, this downregulation of
cytokines was more prominent for proinflammatory cytokines (IL-
1b, TNF-a, and IL-12), suggesting that bovine IL-10 may dampen
Th1 development. The prevention of upregulation of CD40 by
bovine IL-10 prevents activation of DCs by CD40L from activated
T cells and will reduce the activation of naive T cells by DCs.
Moreover, bovine IL-10 can bind to the IL-10Rs expressed on T
cells and directly inhibit their activation [45,46,47].
IL-10 and TGF-b both play a role in tolerance induction [48,49]
and have complimentary suppressive activity [50]. The presence of
intact IL-10 could enhance the success of allergen immunotherapy,
as the presence of IL-10 with an antigen at mucosal sites induces
tolerance to that allergen [33]. The presence of IL-10 in the lumen
resulted in elevated levels of IL-10 producing cells in the Peyers
patch [33]. IL-10 in the lumen may be detected by DCs that
protrude their dendrites through the epithelial cell layer to sample
antigens [41,51] and mouse epithelial cells were proven to express
the IL-10R [52]. In individuals tolerant to mucosal antigens, more
IL-10 dependent regulatory CD4+ cells are present in the periphery
and sublingual allergen immunotherapy induced TGF-b and IL-10
dependent induction of T regulatory cells [50]. CD4+ cells activated
in the presence of IL-10 become anergic and can acquire antigen
specific regulatory activities [30,53].
IL-10 is essential to develop healthy intestinal immunity [54].
That IL-10 present in the lumen can exert biological activity is
Figure 4. Dose-dependent inhibition during LPS-induced DC maturation is comparable for human and bovine IL-10. Data shown are
from 3 different donors tested, error bars indicate standard error. A: Dose dependent inhibition of CD83 (p = 0.753) and CD86 (p = 0.936) by human
and bovine IL-10. Data were divided by the isotype control and expressed relative to the positive control of only LPS, which was set at 100%. B: Dose
dependent inhibition of TNF-a (p = 0.916) and IL-12p70 (p = 0.962) production by human and bovine IL-10, shown in pg/ml.
doi:10.1371/journal.pone.0018188.g004
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shown in a mouse model of autoimmune encephalomyelitis and
diabetes where orally administered IL-10 effectively enhanced
tolerance induction [33]. In addition oral administration of TGF-b
has proven to be functionally active in the intestine when using a
mouse model [55]. Likewise, results from our in vitro experiment
suggest that bovine IL-10 is able to survive and therefore may be
bioactive, particularly in the upper digestive tract of infants. Like
in bovine colostrum, IL-10 is present in human breast milk in
comparable concentrations ranging from 40 pg/ml till 3 ng/ml
[56,57,58]. As infant nutrition is based on resembling breast milk
as much as possible, bovine IL-10 could be considered as a
replacement for the IL-10 present in human breast milk.
Interestingly, the development of necrotizing enterocilitis (NEC)
in premature infants is associated with lower levels of IL-10 in
breast milk [59]. In addition, IL-10 knockout mice develop a
phenotype resembling NEC [54]. Necrotizing enterocolitis
induced in rats can be reversed by human breast milk as well as
IL-10 [34,60], and increased cytoplasmic IL-10 levels in epithelial
cells in rats correlated with protection to NEC [34]. Moreover,
injection of rats with induced NEC with anti TNF-a antibodies
reduced incidence and severity [61]. IL-10 might have similar
local effects as IL-10 is a potent regulator of TNF-a production.
From a meta-analysis of the literature, breastfeeding was
concluded to be associated with a reduced risk for the development
of allergy in the first decade of life [62]. The effect of breastfeeding
may increase with duration of breastfeeding [62]. Next to IL-10,
TGF-b is present in both human and bovine milk. TGF-b1 and
TGF-b2 amino acid sequence identity between cow’s and human
is 95% respectively 98% after removing the signal peptide, and
100% in their cleaved form (own analysis, data not shown), and
therefore are likely to be bioactive in humans. Prolonged
application of a low dose of a cytokine could exert functional
activity, as has been published for IL-2 [63]. Likewise, application
of bovine IL-10 or TFG-b in infant nutrition over a long period
may contribute to the prevention of allergy. Administration of
bovine IL-10 is mainly expected to be advantageous for individuals
with inflammatory diseases, but not for immune-compromised
individuals as IL-10 may further inhibit immune activation.
Additional administration of IL-10 should be done carefully. This
requires further study.
Although several in vivo studies have shown IL-10 bioactivity
after oral administration, a potential drawback of applying bovine
IL-10 in infant nutrition is that to exert its biological effect in the
intestines, bovine IL-10 administered through the diet has to pass
the acidity and digestive enzymes of the human upper digestive
tract. Another challenge would be to adapt current food
processing procedures that currently affect the biological activity
of IL-10 [56]. We do not expect that anti bovine IL-10 antibodies
will appear when bovine is administered orally, and since bovine
IL-10 is bioactive it can inhibit immune cell activation which is a
prerequisite for the development of specific antibodies.
We conclude that bovine IL-10 exerts biological activity
comparable to human IL-10 on human monocytes and DC’s.
These findings may have implications for the induction of immune
tolerance in the intestinal mucosa in patients with intestinal
inflammatory diseases, and for the prevention of NEC and allergy
in infants.
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